|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/6/2009 10:42:03 AM
NEWTOWN, Pa.--(BUSINESS WIRE)--Quinnova Pharmaceuticals, Inc. announced today the launch of Salvax (Hydrating Topical Foam) Rx for the treatment of hyperkeratotic conditions such as psoriasis, keratosis pilaris, and xerosis. Salvax (Hydrating Topical Foam) contains 6% salicylic acid, a potent keratolytic agent, formulated in a water-lipid based foam. The product utilizes Quinnova’s patented Proderm TechnologyTM, containing a unique combination of physiological lipids, dimethicone, and glycerin which together help to restore the skin barrier, hydrate, and protect the skin, in addition to having anti-inflammatory properties.
|
|
|
|
|
|
|
|
|
|
|